Guerbet’s Oxilan Wins Frost & Sullivan Award for Contrast Media with Low Side Effects

 

September 6, 2007

Guerbet’s flagship X-ray contrast agent, Oxilan (ioxilan) injection, is a contrast agent that is a nonionic, low-viscous and low-osmolar monomer.

The 2007 Frost & Sullivan Product Quality Leadership Award is presented to Guerbet for the recognized quality of its contrast media products in the North American Contrast Media Market.

Although there are possible side effects that can arise following injection of X-ray contrast media, Oxilan has had reportedly favorable results with usage feedback, indicating it is a safe product.

Although opacification is a major metric used to judge the quality of contrast media, other significant characteristics such as ionicity, chemical structure, osmolality and viscosity have important influences on their efficacy and safety.

Guerbet has emphasized the point that these additional characteristics can significantly effect visualization, hemodynamics, thrombogenecity, contrast-induced nephropathy and other various clinical outcomes. This emphasis has been implemented in the development of Oxilan, whose chemical characteristics have resulted in high-quality imaging with minimal side effects, according to the manufacturer.